## Temduang Limpaiboon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7577072/publications.pdf

Version: 2024-02-01

		430874	580821	
51	773	18	25	
papers	citations	h-index	g-index	
51	51	51	1406	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Bioinformatic Prediction of Novel Signaling Pathways of Apoptosis-inducing Factor, Mitochondrion-associated 3 (AIFM3) and Their Roles in Metastasis of Cholangiocarcinoma Cells. Cancer Genomics and Proteomics, 2022, 19, 35-49.	2.0	2
2	Combined OPCML and AXL Expression as a Prognostic Marker and OPCML Enhances AXL Inhibitor in Cholangiocarcinoma. In Vivo, 2022, 36, 1168-1177.	1.3	3
3	3D Silk Fibroin-Gelatin/Hyaluronic Acid/Heparan Sulfate Scaffold Enhances Expression of Stemness and EMT Markers in Cholangiocarcinoma. In Vivo, 2022, 36, 1155-1167.	1.3	7
4	Prediction of CIAPIN1 (Cytokine-Induced Apoptosis Inhibitor 1) Signaling Pathway and Its Role in Cholangiocarcinoma Metastasis. Journal of Clinical Medicine, 2022, $11$ , $3826$ .	2.4	0
5	Serum Levels of Cytokine-Induced Apoptosis Inhibitor 1 (CIAPIN1) as a Potential Prognostic Biomarker of Cholangiocarcinoma. Diagnostics, 2021, 11, 1054.	2.6	4
6	<i>OPCML</i> Exerts Antitumor Effects in Cholangiocarcinoma <i>via</i> AXL/STAT3 Inactivation and Rho GTPase Down-regulation. Cancer Genomics and Proteomics, 2021, 18, 771-780.	2.0	4
7	Apoptosis-Inducing Factor, Mitochondrion-Associated 3 (AIFM3) Protein Level in the Sera as a Prognostic Marker of Cholangiocarcinoma Patients. Biomolecules, 2020, 10, 1021.	4.0	5
8	Interleukin 25 (IL‑25) expression in cholangiocarcinoma. Molecular and Clinical Oncology, 2020, 13, 1-1.	1.0	3
9	Serum coiled‑coil domain containing 25 protein as a potential screening/diagnostic biomarker for cholangiocarcinoma. Oncology Letters, 2020, 19, 930-942.	1.8	5
10	Serum Cystatin C as a Potential Marker for Glomerular Filtration Rate in Patients with Cholangiocarcinoma. International Journal of Hematology-Oncology and Stem Cell Research, 2020, 14, 157-166.	0.3	1
11	Genomic Profiling of Biliary Tract Cancer Cell Lines Reveals Molecular Subtypes and Actionable Drug Targets. IScience, 2019, 21, 624-637.	4.1	15
12	Serum Apurinic/Apyrimidinic Endodeoxyribonuclease 1 (APEX1) Level as a Potential Biomarker of Cholangiocarcinoma. Biomolecules, 2019, 9, 413.	4.0	15
13	Serum pyruvate dehydrogenase kinase as a prognostic marker for cholangiocarcinoma. Oncology Letters, 2019, 17, 5275-5282.	1.8	11
14	Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma. Pathology Research and Practice, 2019, 215, 152451.	2.3	15
15	Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases. Clinical Epigenetics, 2019, 11, 39.	4.1	40
16	The Upregulation of OCT4 in Acidic Extracellular pH is Associated with Gemcitabine Resistance in Cholangiocarcinoma Cell Lines. Asian Pacific Journal of Cancer Prevention, 2019, 20, 2745-2748.	1.2	8
17	Biomimetic scaffolds and dynamic compression enhance the properties of chondrocyte―and <scp>MSC</scp> â€based tissueâ€engineered cartilage. Journal of Tissue Engineering and Regenerative Medicine, 2018, 12, 1220-1229.	2.7	35
18	Chitinase 3 like 1 (CHI3L1) promotes vasculogenic mimicry formation in cervical cancer. Pathology, 2018, 50, 293-297.	0.6	21

#	Article	IF	Citations
19	The development of simultaneous measurement of viral load and physical status for human papillomavirus 16 and 18 coâ€infection using multiplex quantitative polymerase chain reaction. Oncology Letters, 2018, 16, 6977-6987.	1.8	4
20	Synergistic effects of cisplatin-caffeic acid induces apoptosis in human cervical cancer cells via the mitochondrial pathways. Oncology Letters, 2018, 15, 7397-7402.	1.8	27
21	Classification of Gemcitabine resistant Cholangiocarcinoma cell lines using synchrotron FTIR microspectroscopy. Journal of Biophotonics, 2017, 10, 367-376.	2.3	11
22	High expression of CCDC25 in cholangiocarcinoma tissue samples. Oncology Letters, 2017, 14, 2566-2572.	1.8	10
23	Diagnostic value of serum bile acid composition patterns and serum glycocholic acid levels in cholangiocarcinoma. Oncology Letters, 2017, 14, 4943-4948.	1.8	12
24	Aberrant methylation of HTATIP2 and UCHL1 as a predictive biomarker for cholangiocarcinoma. Molecular Medicine Reports, 2017, 17, 4145-4153.	2.4	10
25	High expression of apoptosis-inducing factor, mitochondrion-associated 3 (AIFM3) in human cholangiocarcinoma. Tumor Biology, 2016, 37, 13659-13667.	1.8	15
26	The evaluation of loop-mediated isothermal amplification-quartz crystal microbalance (LAMP-QCM) biosensor as a real-time measurement of HPV16 DNA. Journal of Virological Methods, 2016, 229, 8-11.	2.1	28
27	Targeted delivery of 5-fluorouracil to cholangiocarcinoma cells using folic acid as a targeting agent. Materials Science and Engineering C, 2016, 60, 411-415.	7.3	28
28	Targeting the î"133p53 isoform can restore chemosensitivity in 5-fluorouracil-resistant cholangiocarcinoma cells. International Journal of Oncology, 2015, 47, 2153-2164.	3.3	18
29	DNA methylation level of OPCML and SFRP1: a potential diagnostic biomarker of cholangiocarcinoma. Tumor Biology, 2015, 36, 4973-4978.	1.8	25
30	Silk fibroin/gelatin–chondroitin sulfate–hyaluronic acid effectively enhances in vitro chondrogenesis of bone marrow mesenchymal stem cells. Materials Science and Engineering C, 2015, 52, 90-96.	7.3	50
31	TRAIL in Combination with Subtoxic 5-FU Effectively Inhibit Cell Proliferation and Induce Apoptosis in Cholangiocarcinoma Cells. Asian Pacific Journal of Cancer Prevention, 2015, 16, 6991-6996.	1.2	6
32	Fabrication and characterization of silk fibroin–gelatin/chondroitin sulfate/hyaluronic acid scaffold for biomedical applications. Materials Letters, 2014, 126, 207-210.	2.6	18
33	Chitinase 3 like 1 is associated with tumor angiogenesis in cervical cancer. International Journal of Biochemistry and Cell Biology, 2014, 51, 45-52.	2.8	31
34	Discrimination of micromass-induced chondrocytes from human mesenchymal stem cells by focal plane array-Fourier transform infrared microspectroscopy. Talanta, 2014, 130, 39-48.	5.5	8
35	Aberrant DNA Methylation at Genes Associated with a Stem Cell-like Phenotype in Cholangiocarcinoma Tumors. Cancer Prevention Research, 2013, 6, 1348-1355.	1.5	24
36	Histone Deacetylases and their Inhibitors as Potential Therapeutic Drugs for cholangiocarcinoma - Cell Line findings. Asian Pacific Journal of Cancer Prevention, 2013, 14, 2503-2508.	1.2	25

3

#	Article	IF	CITATIONS
37	Validation of methylation-sensitive high resolution melting for the detection of DNA methylation in cholangiocarcinoma. Clinical Biochemistry, 2012, 45, 1092-1094.	1.9	14
38	Contribution of RIZ1 to Regulation of Proliferation and Migration of a Liver Fluke-Related Cholangiocarcinoma Cell. Asian Pacific Journal of Cancer Prevention, 2012, 13, 4007-4011.	1.2	4
39	Epigenetic aberrations in cholangiocarcinoma: potential biomarkers and promising target for novel therapeutic strategies. Asian Pacific Journal of Cancer Prevention, 2012, 13 Suppl, 41-5.	1.2	4
40	Serum adhesion molecule-1 (ICAM-1) as a potential prognostic marker for cholangiocarcinoma patients. Asian Pacific Journal of Cancer Prevention, 2012, 13 Suppl, 107-14.	1.2	6
41	Characterisation of chondrogenic differentiation of human mesenchymal stem cells using synchrotron FTIR microspectroscopy. Analyst, The, 2011, 136, 2542.	3.5	26
42	Verification of complete bisulfite modification using Calponin-specific primer sets. Clinical Biochemistry, 2010, 43, 528-530.	1.9	15
43	Genetic and epigenetic alterations of RIZ1 and the correlation to clinicopathological parameters in liver fluke-related cholangiocarcinoma. Experimental and Therapeutic Medicine, 2010, 1, 385-390.	1.8	6
44	Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma. World Journal of Gastroenterology, 2010, 16, 1631.	3.3	14
45	Preferentially different mechanisms of inactivation of 9p21 gene cluster in liver fluke–related cholangiocarcinoma. Human Pathology, 2009, 40, 817-826.	2.0	23
46	Amplification of chromosome 21q22.3 harboring trefoil factor family genes in liver fluke related cholangiocarcinoma is associated with poor prognosis. World Journal of Gastroenterology, 2006, 12, 4143.	3.3	20
47	Amplification of D22S283 as a favorable prognostic indicator in liver fluke related cholangiocarcinoma. World Journal of Gastroenterology, 2006, 12, 4338.	3.3	10
48	Prognostic significance of microsatellite alterations at 1p36 in cholangiocarcinoma. World Journal of Gastroenterology, 2006, 12, 4377.	3.3	20
49	Promoter hypermethylation is a major event of hMLH1 gene inactivation in liver fluke related cholangiocarcinoma. Cancer Letters, 2005, 217, 213-219.	7.2	34
50	Anti-p53 antibodies and p53 protein expression in cholangiocarcinoma. Hepato-Gastroenterology, 2004, 51, 25-8.	0.5	4
51	Microsatellite alterations in liver fluke related cholangiocarcinoma are associated with poor prognosis. Cancer Letters, 2002, 181, 215-222.	7.2	29